Ocugen
Ocugen, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies aimed at treating eye diseases. The company's pipeline includes several promising candidates, such as OCU200, a fusion protein in preclinical development for conditions like wet age-related macular degeneration (AMD) and diabetic retinopathy. Additionally, OCU400 is being developed to address retinitis pigmentosa, while OCU410 targets dry AMD. Ocugen is also advancing a modifier gene therapy platform, which has the potential to treat various retinal disorders with a single therapeutic approach. The company has established a strategic partnership with CanSino Biologics to support the co-development and manufacturing of gene therapies. Headquartered in Malvern, Pennsylvania, Ocugen aims to provide transformative solutions for patients facing significant visual impairments.
Histogenics Corporation, based in Waltham, Massachusetts, specializes in regenerative medicine with a focus on developing therapies for musculoskeletal conditions. Founded in 2000, the company aims to create innovative solutions for cartilage damage and joint function restoration. Its primary product candidate, NeoCart®, is a tissue implant designed to regenerate healthy cartilage and improve orthopedic outcomes, particularly for knee injuries. By integrating expertise in cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors, Histogenics seeks to address degenerative diseases and enhance patient recovery through its advanced regenerative medicine platform. In 2019, Histogenics was acquired by Ocugen, Inc. in a reverse merger transaction.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.